Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Zachery Reichert, M.D.
University of Michigan Rogel Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan Hospital
Ann Arbor, Michigan, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- University of Virginia Health System
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2019
- Primary completion
- 26 Jan 2023
- Completion
- 31 Aug 2028
- Last update posted
- 23 Mar 2026
- Registered enrollment
- 49
- Registry id
- NCT03787680
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.